Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 6/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806161 | 0.80 | KMT2A (0.45) | NPSR1HPGDUSP2LMNAHSD17B10 | |
| SCHEMBL23840126 | 0.69 | NOS3 (0.39) | HPGDLMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL18999656 | 0.69 | GABRA1 (0.37) | HPGDLMNAKMT2AALDH1A1PNP | |
| SCHEMBL12110225 | 0.68 | ACLY (0.35) | HPGDLMNAKMT2AALDH1A1PNP | |
| SCHEMBL17661910 | 0.68 | GABRA1 (0.42) | HPGDKMT2AALDH1A1PNPMEN1 | |
| SCHEMBL18254476 | 0.68 | QPCT (0.33) | HPGDKMT2AALDH1A1PNPMEN1 | |
| SCHEMBL22433010 | 0.66 | MAPT (0.50) | ALDH1A1KDM4EMAPTHTT | |
| SCHEMBL7846846 | 0.66 | BRD4 (0.40) | NPSR1HPGDLMNAKMT2AALDH1A1 | |
| SCHEMBL23742733 | 0.66 | MAPT (0.46) | ALDH1A1KDM4EBRD4MAPTHTT | |
| SCHEMBL17127786 | 0.66 | PNP (0.33) | HPGDKMT2AALDH1A1PNPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251493-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | SEIWERT SCOTT D (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | NPSR1 4141/4885HPGD 1047/4885USP2 2287/4885 |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | NPSR1 4817/4885HPGD 2820/4885USP2 2540/4885 |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HDGF | NPSR1 4563/4885HPGD 3046/4885USP2 1172/4885 |
| US-20120251493-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | NPSR1 4799/4885HPGD 2680/4885USP2 2185/4885 |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | NPSR1 4817/4885HPGD 2820/4885USP2 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.